• Inherits advantages of traditional small-molecule drugs
• Targets previously "undruggable" complex proteins (e.g., scaffold proteins)
• Significantly expands potential drug target scope
• Unique catalytic property enables repeated degradation cycles
• Supports lower doses, reducing potential side effects

Pamplona's ASTRIDE^® platform delivers major breakthroughs through deep integration of TPD technology with AI algorithms